Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study
01:32pm, Friday, 25'th Aug 2023
Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.
Novo Nordisk's Wegovy Helped Heart-Failure Patients. What's Next?
12:31pm, Friday, 25'th Aug 2023
Proof that new weight-loss drugs will transform healthcare was bolstered with the news that heart-failure patients were helped by Novo Nordisk's drug Wegovy.
Novo Nordisk obesity drug Wegovy eases symptoms of heart failure, study finds
08:07am, Friday, 25'th Aug 2023
The Novo Nordisk NVO, -2.47% obesity drug semaglutide, marketed as Wegovy, can significantly reduce symptoms related to heart failure, according to a study published Friday in the New England Journal
Novo Nordisk CEO Lars Fruergaard Jorgensen at Reuters Newsmaker event
07:55am, Friday, 25'th Aug 2023
Novo Nordisk CEO Lars Fruergaard Jorgensen spoke at a Reuters Newsmaker event on Friday. Below are some quotes from his interview which focused on the company's hugely popular Wegovy weight-loss drug.
Novo Nordisk to address social inequality in dialogue with healthcare systems -CEO
05:29am, Friday, 25'th Aug 2023
Novo Nordisk CEO Lars Fruergaard Jorgensen said on Friday the company will work with European government healthcare systems to ensure less fortunate and the most obese people get access to its Wegovy
This New Development Is Helping to Send Eli Lilly and Novo Nordisk Stocks Soaring
10:23am, Thursday, 24'th Aug 2023
A new study by Novo Nordisk points to GLP-1 drugs reducing cardiac risks. It's a relevant finding for Eli Lilly, too, which is already moving forward in clinical trials.
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
05:40am, Thursday, 24'th Aug 2023
The active ingredient in Ozempic could be useful for quite a few conditions. Cardiovascular disease, certain chronic liver diseases, and addiction are just a few.
Why Novo Nordisk Stock Was Racing Higher on Wednesday
02:57pm, Wednesday, 23'rd Aug 2023
Not surprisingly, this had to do with its highly popular weight-loss drug. A second contract manufacturer for Wegovy has been identified.
Could This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?
10:15am, Tuesday, 22'nd Aug 2023
Novo Nordisk and Eli Lilly want to use their medicines to treat NASH, a liver disease. Their chances of success are more uncertain than shareholders might wish to see.
These 3 Large-Cap Pharma Stocks Have Been Red-Hot
09:02pm, Monday, 21'st Aug 2023
Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.
How soaring demand for Ozempic and Wegovy is altering Denmark's economy
11:52am, Monday, 21'st Aug 2023
The dazzling success of weight-loss drugs in the United States is leading to lower interest rates in Denmark, home of one of their biggest manufacturers, according to the Nordic country's biggest bank
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
11:16am, Monday, 21'st Aug 2023
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are wo
Ozempic Just Got Even Better for Novo Nordisk Stock
08:30am, Sunday, 20'th Aug 2023
Ozempic is practically flying off the shelves to treat diabetes and obesity. The drug could also be useful in reducing cardiac event risk, per a new study.
3 Fantastic Stocks to Buy in a New Bull Market
06:54am, Sunday, 20'th Aug 2023
Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.
Americans are paying dramatically higher prices for weight-loss drugs like Ozempic, report finds
11:34am, Friday, 18'th Aug 2023
Weight-loss drugs are substantially more expensive in the US than in other comparably large, high-income countries, according to a new analysis from the health policy organization KFF. The analysis co
